Table 3 Patients’ characteristics
No. of patients | Age (years) | Sex | WHO* | Primary cancer | Mutations and Biomarkers | Concomitant systemic medication | Level | Presenting symptoms | Muscular strength at diagnosis | Use of corticosteroids | Time between diagnostic to start of SBRT (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 67 | M | 2–3 | Lung, adenocarcinoma | EGFR- / ALK- PD-L1 70% | No | T10 | Total paraplegia | 0/5 | No | 14 |
2 | 69 | F | 1 | Lung, adenocarcinoma | EGFR- / ALK- / KRAS- | No | T11 | Posterior cord syndrome | 4/5 | No | 21 |
3 | 72 | M | 2 | Kidney, clear cell carcinoma | x | No | L2 | Partial paraplegia | 3/5 | Yes (1 mg/kg) | 6 |
4 | 33 | M | 0 | Skin, melanoma | x | NIVOLUMAB | T8 | None | 5/5 | No | 33 |
5 | 62 | F | 1 | Breast, adenocarcinoma | HER +++ / HR + | TRASTUZUMAB PERTUZUMAB | C4 | None | 5/5 | Yes (1 mg/kg) | 44 |